Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 6
2022 18
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Covaxin: An overview of its immunogenicity and safety trials in India.
Sharma R, Tiwari S, Dixit A. Sharma R, et al. Bioinformation. 2021 Oct 31;17(10):840-845. doi: 10.6026/97320630017840. eCollection 2021. Bioinformation. 2021. PMID: 35574502 Free PMC article. Review.
The ability to induceT-helper-1 cell (Th1) responses is desirable from an effective vaccine against this virus. Covaxin (BBV152) is a wholevirion inactivated SARS-CoV-2 vaccine adjuvanted with Algel-Imidazoquinoline (IMDG) molecule, a toll-like receptor (TLR) 7/8 agonist. …
The ability to induceT-helper-1 cell (Th1) responses is desirable from an effective vaccine against this virus. Covaxin (BBV152) is a …
Covid-19 vaccines and variants of concern: A review.
Hadj Hassine I. Hadj Hassine I. Rev Med Virol. 2022 Jul;32(4):e2313. doi: 10.1002/rmv.2313. Epub 2021 Nov 9. Rev Med Virol. 2022. PMID: 34755408 Free PMC article. Review.
All nine had an efficacy over 50% against symptomatic Covid-19 disease: NVX-CoV2373 (96%), BNT162b2 (95%), mRNA-1273 (94%), Sputnik V (92%), AZD1222 (81%), BBIBP-CorV (79%), Covaxin (78%), Ad26.CoV.S (66%) and CoronaVac (51%). However, vaccine efficacy (VE) can be jeopardi …
All nine had an efficacy over 50% against symptomatic Covid-19 disease: NVX-CoV2373 (96%), BNT162b2 (95%), mRNA-1273 (94%), Sputnik V (92%), …
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review.
Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Das S, et al. Immunol Res. 2022 Jun;70(3):289-315. doi: 10.1007/s12026-022-09265-0. Epub 2022 Feb 22. Immunol Res. 2022. PMID: 35192185 Free PMC article. Review.
On the 13th of January 2021, the vaccination campaign against SARS-CoV-2 was launched in India and started the administration of two types of vaccines known as Covaxin and Covishield. Covishield is an adenovirus vector-based vaccine, and Covaxin was developed by a t …
On the 13th of January 2021, the vaccination campaign against SARS-CoV-2 was launched in India and started the administration of two types o …
Inactivated vaccine Covaxin/BBV152: A systematic review.
Ahmed TI, Rishi S, Irshad S, Aggarwal J, Happa K, Mansoor S. Ahmed TI, et al. Front Immunol. 2022 Aug 9;13:863162. doi: 10.3389/fimmu.2022.863162. eCollection 2022. Front Immunol. 2022. PMID: 36016940 Free PMC article.
The immunogenicity performance of Covaxin, which provided significant protection only after the second dose, was mediocre and it was consistently surpassed by Covishield. ...There was some evidence of coverage against the Alpha, Beta, and Delta variants. However, neither …
The immunogenicity performance of Covaxin, which provided significant protection only after the second dose, was mediocre and it was …
A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review.
Talukder A, Kalita C, Neog N, Goswami C, Sarma MK, Hazarika I. Talukder A, et al. Z Naturforsch C J Biosci. 2022 Mar 2;77(7-8):351-362. doi: 10.1515/znc-2021-0301. Print 2022 Jul 26. Z Naturforsch C J Biosci. 2022. PMID: 35245422 Free article. Review.
Based on these parameters this review aims to critically assess the efficacy of Covaxin and compare it with other vaccines in the WHO EUL list and perform a comparative analysis of COVID-19 vaccines which are in phase 3 and phase 4 of clinical trials. This will help us det …
Based on these parameters this review aims to critically assess the efficacy of Covaxin and compare it with other vaccines in the WHO …
Covid-19 Vaccines Available in India.
Mukim M, Sharma P, Patweker M, Patweker F, Kukkar R, Patel R. Mukim M, et al. Comb Chem High Throughput Screen. 2022;25(14):2391-2397. doi: 10.2174/1386207325666220315115953. Comb Chem High Throughput Screen. 2022. PMID: 35293291 Review.
The present review covers the list of approved vaccines available in India, i.e., Covaxin, Covishield, and Sputnik-V. Covaxin's code name is BBV152. Covaxin was prepared by Hyderabad- based Bharat Biotech International Ltd. in collaboration with the National …
The present review covers the list of approved vaccines available in India, i.e., Covaxin, Covishield, and Sputnik-V. Covaxin' …
Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis.
Shafiee A, Amini MJ, Arabzadeh Bahri R, Jafarabady K, Salehi SA, Hajishah H, Mozhgani SH. Shafiee A, et al. Eur J Med Res. 2023 Aug 10;28(1):278. doi: 10.1186/s40001-023-01238-9. Eur J Med Res. 2023. PMID: 37559096 Free PMC article. Review.
There were several vaccines that caused reactivation including BNT162b2 mRNA or Pfizer-BioNTech (n = 76), Oxford-AstraZeneca (n = 22), mRNA-1273 or Moderna (n = 17), Sinovac (n = 4), BBIBP-CorV or Sinopharm (n = 3), Covaxin (n = 3), Covishield (n = 3), and Johnson and John …
There were several vaccines that caused reactivation including BNT162b2 mRNA or Pfizer-BioNTech (n = 76), Oxford-AstraZeneca (n = 22), mRNA- …
The Vaccine World of COVID-19: India's Contribution.
Chavda VP, Vihol DR, Solanki HK, Apostolopoulos V. Chavda VP, et al. Vaccines (Basel). 2022 Nov 17;10(11):1943. doi: 10.3390/vaccines10111943. Vaccines (Basel). 2022. PMID: 36423038 Free PMC article. Review.
Vaccination is the most effective and best way to avoid the disease of COVID-19.
Lotfi H, Mazar MG, Ei NMH, Fahim M, Yazdi NS. Lotfi H, et al. Immun Inflamm Dis. 2023 Aug;11(8):e946. doi: 10.1002/iid3.946. Immun Inflamm Dis. 2023. PMID: 37647441 Free PMC article. Review.
Among the inactive viral vaccines, the following can be mentioned: CoronaVac (Sinovac) WIBP vaccine (Wuhan Institute of Biological Products, Sinopharm), BBIBPCorV (Beijing Institute of Biological Products, Sinopharm), BBV152/Covaxin (Bharat Biotech, ICMR, National Institut …
Among the inactive viral vaccines, the following can be mentioned: CoronaVac (Sinovac) WIBP vaccine (Wuhan Institute of Biological Products, …
30 results